Synlogic Inc (SYBX) Share Price

SYBX under $2

SYBX under $2

SYBX new 52 week low

SYBX new 52 week low

SYBX new 52 week low

SYBX new 52 week low

SYBX 0.55 +9% after 0.56 looks like breakout coming..


Ticker Buzz Cloud
24 Hours
12 Hours
6 Hours
3 Hours
1 Hour
AABB
AAPL
AHRO
AITX
AMC
AMIH
ATMH
AVXL
BDPT
BTTX
CBD
CDSG
CLNV
CORZQ
CRGP
CYXTQ
DBMM
DLOC
DWAC
ECDD
ENZC
EPAZ
FTEG
GEGI
GRST
GVSI
HHSE
IFUS
INKW
IQST
JPM
LWLG
MGOL
MGRX
MIKP
MMTMF
MMY
MSFT
MULN
NSAV
NWBO
PWM
RIVN
RNVA
SNPW
SNTX
SRMX
TMC
TSLA
TTOO
XCRT

$SYBX - Up 9% Pre-Market/ Current Price $0.55
Granted Fast Track Designation from FDA for labafenogene marselecobac (SYNB1934) for Treatment of Phenylketonuria

SYBX 0.554 +10%


Ticker Buzz Cloud
24 Hours
12 Hours
6 Hours
3 Hours
1 Hour
AABB
AAPL
AHRO
AITX
AMC
AMIH
ATMH
AVXL
BDPT
BTTX
CBD
CDSG
CLNV
CORZQ
CRGP
CYXTQ
DBMM
DLOC
DWAC
ECDD
ENZC
EPAZ
FTEG
GEGI
GRST
GVSI
HHSE
IFUS
INKW
IQST
JPM
LWLG
MGOL
MGRX
MIKP
MMTMF
MMY
MSFT
MULN
NSAV
NWBO
PWM
RIVN
RNVA
SNPW
SNTX
SRMX
TMC
TSLA
TTOO
XCRT

SYBX new 52 week low

smh why this baby’s not running

Why is it not running?

Synlogic Receives Orphan Drug Designation from FDA for SYNB1934 for Treatment of Phenylketonuria
CAMBRIDGE, Mass., May 09, 2023 (GLOBE NEWSWIRE) -- Synlogic, Inc. (Nasdaq: SYBX), the leading company advancing therapeutics based on synthetic biology, today announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation (ODD) to SYNB1934 for the treatment of phenylketonuria (PKU).

“We are very pleased that SYNB1934 has been granted another regulatory designation, further validating the need for new treatment options for those living with PKU,” said Aoife Brennan M.B. Ch.B., Synlogic President and Chief Executive Officer. “This designation also comes at a pivotal time as we prepare to initiate our Phase 3 trial for PKU – Synpheny-3— in the first half of this year.”

ODD is granted by the FDA to drugs or biologics intended to treat a rare disease or condition, which generally affects less than 200,000 individuals in the U.S. ODD granted therapies entitle companies to development incentives including tax credits for qualified clinical trials, user fee exemptions, and the potential for seven years of market exclusivity after approval.

SYNB1934 has also received Rare Pediatric Disease Designation (RPDD) from the FDA and orphan designation from the European Medicines Agency (EMA).

About SYNB1934

SYNB1934 is an orally administered, non-systemically absorbed drug candidate being studied as potential biotherapeutic for phenylketonuria (PKU). PKU is an inherited rare metabolic disease caused by an inborn error of metabolism that impairs the breakdown of phenylalanine (Phe), an amino acid found in all protein-containing foods. Treatment options for PKU are currently limited, with a majority of individuals with PKU in need of treatment or not adequately responding to treatment. Synlogic designed SYNB1934 to reduce levels of Phe in people with PKU by consuming Phe in the gastrointestinal (GI) tract, using genetic engineering of the well-characterized probiotic E. coli Nissle. Findings to date support the potential for an oral, efficacious, safe, convenient, and flexible treatment option for PKU. SYNB1934 has been granted Rare Pediatric Disease and Orphan Drug designations by the U.S. Food and Drug Administration (FDA) and orphan designation from the European Medicines Agency (EMA).

About Synlogic

Synlogic is the leading company advancing therapeutics based on synthetic biology. Synlogic’s pipeline includ

Still here. I think this is finally bottoming out. Good luck all !

Good morning Synlogic Shareholders , future investors and visitors. Today the stars may align and bless us with profits. with the continued low asking price along with Charden"s upgrade from 5 to a 10 dollar stock making this stock ready to run. Good luck all!

Welcome and good luck .this stock is poise to run if we can just get the news out low shares on the ask.

Grabbed a starter yesterday.

If this news gets out , it may have a chance to double. have to wait and see.

The news need to spread to get this stock moving!

"*Synlogic shares are trading higher after Chardan raised its price target on the stock from $5 to $10.
Benzinga"
This stock is under the radar!

There's news out today!

Hey is any one here

* * $SYBX Video Chart 12-14-2020 * *

Link to Video - click here to watch the technical chart video

https://www.cnbc.com/video/2019/06/13/ginkgo-bioworks-and-synlogic-to-collaborate-on-living-medicine.html

On June 11, 2019, Synlogic, Inc. (the “ Company ”) entered into a Subscription Agreement (the “ Subscription Agreement ”) with Ginkgo Bioworks, Inc. (“ Ginkgo ”), providing for the issuance and sale by the Company to Ginkgo of an aggregate of (i) 6,340,771 shares (the “ Shares ”) of the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), at a purchase price per Share of $9.00, and (ii) pre-funded warrants to purchase an aggregate of 2,548,117 shares of Common Stock (the “ Pre-Funded Warrants ”) at an exercise price of $9.00 per Share (the “ Offering ”), with $8.99 of such exercise price paid at the closing of the Offering. The gross proceeds to the Company will be approximately $80 million. The closing of the Offering took place on June 11, 2019.

https://secfilings.nasdaq.com/filingFrameset.asp?FilingID=13487245&RcvdDate=6/12/2019&CoName=SYNLOGIC,%20INC.&FormType=8-K&View=html

11/25/2020 Day Chart:

Synlogic has a platform collaboration agreement with Ginkgo Bioworks to aid in strain optimization and development.

https://www.synlogictx.com/collaborations/

NOVEMBER 25, 2020
U.S. loans $1.1 billion to Ginkgo Bioworks for pandemic effort

https://www.reuters.com/article/idUSKBN2851TA

https://www.secform4.com/insider-trading/1527599.htm

SYBX 1.85 - currently trading at less than 1/2 cash with several programs in the pipeline...

SARS-CoV2 Vaccine Initiative

Synlogic is evaluating its Synthetic Biotic platform for the development of a vaccine for the prevention of SARS-CoV2.

https://www.synlogictx.com/pipeline-programs/#sars